Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18330368 | 0.82 | ALDH1A1 (0.56) | THRBMEN1KMT2AGAAHPGD | |
| SCHEMBL2610804 | 0.82 | HPGD (0.42) | EPHX2THRBATML3MBTL1MEN1 | |
| SCHEMBL11955634 | 0.81 | EPHX2 (0.39) | EPHX2THRBATML3MBTL1MEN1 | |
| SCHEMBL8341984 | 0.78 | EPHX2 (0.47) | EPHX2MEN1KMT2AALDH1A1 | |
| SCHEMBL8342259 | 0.77 | EPHX2 (0.48) | EPHX2THRBATML3MBTL1MEN1 | |
| SCHEMBL18508520 | 0.76 | ROCK2 (0.44) | EPHX2MEN1KMT2AALDH1A1TP53 | |
| SCHEMBL18562931 | 0.76 | ROCK2 (0.44) | EPHX2MEN1KMT2AALDH1A1TP53 | |
| SCHEMBL17207616 | 0.76 | EPHX2 (0.47) | EPHX2THRBATML3MBTL1MEN1 | |
| SCHEMBL1487944 | 0.75 | THRB (0.68) | THRBATML3MBTL1MEN1KMT2A | |
| SCHEMBL10627932 | 0.73 | CA2 (0.38) | MEN1KMT2AGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889831-B2 | Unit dosage forms of pharmaceutical compositions comprising a polymer-factor VIII polypeptide conjugate | NEKTAR THERAPEUTICS (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120178692-A1 | DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178692-A1 | DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | EPHX2 209/4885THRB 3907/4885ATM 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.